-
2024-515297-27-00
5
2024-08-14
colon carcinoma
-
2023-508260-30-01
5
2024-07-30
Patients with poor prognostic OVARian cancers based on the tumor prima
-
2024-515788-73-00
4
2024-07-30
MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND
A HIGH IM
-
2024-514083-31-00
4
2024-07-26
squamous cell anal carcinoma
-
2024-512872-36-00
5
2024-07-25
obstetric_pathological delivery
-
2023-509571-16-00
3
2024-07-17
Lung Cancer
-
2023-509572-42-00
3
2024-07-17
Lung Cancer
-
2024-511309-47-00
4
2024-07-17
moderate thrombocytopenia
-
2023-507641-29-00
4
2024-07-15
Locally Advanced or Metastatic Solid Tumors
-
2023-504962-52-00
5
2024-07-10
Triple negative breast cancer.
-
2023-508178-27-00
9
2024-07-10
Participants with Advanced KRASG12C-Mutated Solid Tumors
-
2023-510536-37-00
4
2024-07-05
Prostate Cancer
-
2024-518259-49-00
5
2024-07-04
Mental Disorder
-
2024-512004-19-01
5
2024-07-02
Head trauma
-
2022-502956-29-00
5
2024-07-01
Oligometastatic prostate cancer (OMPC)
-
2023-505112-38-00
11
2024-07-01
recently active non-infectious intermediate, posterior, and pan-uveiti
-
2023-507914-28-00
10
2024-06-19
Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade
-
2023-503886-44-00
5
2024-06-10
Patients with a histological diagnosis of p53abn HREC, treated with cu
-
2023-505214-23-00
5
2024-06-07
colon carcinoma
-
2023-506721-11-00
5
2024-06-04
Familial Mediterranean Fever (FMF)
-
2023-505436-35-00
5
2024-06-03
Untreated FLIPI 2-5 Follicular Lymphoma
-
2023-504251-27-00
7
2024-05-27
Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mut
-
2023-506282-66-00
5
2024-05-27
Women with ER+ HER2- metastatic breast cancer who progressed on first
-
2022-501590-39-00
1
2024-05-22
Solid Tumor